Rachelle Broveleit, PA
Physician Assistant · Sioux Falls, SDNPI 1588788160
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.9% of the total across 324 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,444 and has fallen 59.6% since, to $584 in 2025. Among physician assistant clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 324 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$699
- Teva Pharmaceuticals USA, Inc.$670
- Otsuka America Pharmaceutical, Inc.$669
- AbbVie$519
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$329
- Tris Pharma Inc$292
- plus $2K from 19 others
What the payments were for
- Food & beverage$4,77491%
- Education$4759%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 51 | $699 |
| Teva Pharmaceuticals USA, Inc. | 27 | $670 |
| Otsuka America Pharmaceutical, Inc. | 43 | $669 |
| AbbVie | 44 | $519 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $329 |
| Tris Pharma Inc | 11 | $292 |
| Alkermes, Inc. | 11 | $237 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $220 |
| Vanda Pharmaceuticals Inc. | 9 | $205 |
| Lundbeck LLC | 11 | $205 |
| Idorsia Pharmaceuticals US Inc | 16 | $193 |
| Jazz Pharmaceuticals Inc. | 11 | $183 |
| Corium, LLC | 17 | $182 |
| Neurocrine Biosciences, Inc. | 7 | $114 |
| Johnson & Johnson | 7 | $110 |
| Merck | 6 | $84 |
| Harmony Biosciences LLC | 4 | $67 |
| Acadia Pharmaceuticals Inc | 3 | $50 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Almatica Pharma LLC | 3 | $45 |
| Eisai Inc. | 2 | $38 |
| Avanir Pharmaceuticals, Inc. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Biogen | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$264
- Dyanavel XR$124
- Quillivant$124
- Quillichew ER$124
How this compares
$5,249 in reported general payments places this provider in the 95th percentile of 548 physician assistant providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 19 | $55,058 |
| CaplytaLumateperone Tosylate | 27 | $20,601 |
| VyvanseLisdexamfetamine Dimesylate | 36 | $13,596 |
| RexultiBrexpiprazole | 16 | $11,263 |
| Bupropion XlBupropion Hcl | 328 | $9,334 |
| Lurasidone Hcl | 31 | $8,044 |
| Aripiprazole | 113 | $3,931 |
| Duloxetine Hcl | 183 | $3,483 |
| Hydroxyzine Hcl | 135 | $3,438 |
| Methylphenidate ErMethylphenidate Hcl | 17 | $3,357 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 200 | $2,986 |
| Lisdexamfetamine Dimesylate | 19 | $2,864 |
| Quetiapine Fumarate | 156 | $2,473 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 50 | $2,215 |
| Divalproex Sodium ErDivalproex Sodium | 18 | $2,133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $110 | $55,05819 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $329 | $20,60127 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $220 | $13,59636 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $669 | $11,26316 claims |
| Almatica Pharma LLCSertraline Hcl | $45 | $1,272169 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 548 physician assistant providers in South Dakota.
Other physician assistant in Sioux Falls
- Kimberly NelsonSioux Falls$11K
- Christina PekoskeSioux Falls$9K
- Rachel HotvetSioux Falls$8K
- Gabriel PenaredondoSioux Falls$7K
- Virginia LemmeSioux Falls$6K
- Kathrine JibbenSioux Falls$6K
- Austen FagerlandSioux Falls$6K
- Cheryle BrandtSioux Falls$6K
- Stephanie SteltonSioux Falls$5K
- Joseph NewmanSioux Falls$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.